Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters








Database
Language
Publication year range
1.
Cancer Treat Rep ; 70(10): 1167-71, 1986 Oct.
Article in English | MEDLINE | ID: mdl-3756939

ABSTRACT

Chlorpromazine (CPZ) and caffeine (CFN) enhance the cytotoxicity of nitrosoureas in conventional murine tumor systems, but this effect was not confirmed in a randomized clinical trial which compared the action of semustine (MeCCNU) against the combination of MeCCNU, CPZ, and CFN. Since differences in repair systems are known to exist between cells of human or murine origin, we have employed a human melanoma xenograft system to quantify the drug interaction. The enhancement in human melanoma cells was similar to that observed with conventional murine tumor systems. Alkaline elution studies and determination of radioactivity from labeled MeCCNU pointed to increased drug retention and fixation of DNA damage as the mechanism of enhancement. Although toxicity studies were limited to murine tissues, there was evidence of increased toxicity, especially if MeCCNU was combined with both CPZ and CFN. Thus, a true therapeutic synergism may not be present for the combination. Some explanations for the failure to detect such drug interaction in clinical trials and the relevance of advanced preclinical tumor systems are discussed.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Melanoma/drug therapy , Nitrosourea Compounds/therapeutic use , Semustine/therapeutic use , Animals , Antineoplastic Combined Chemotherapy Protocols/toxicity , Bone Marrow/drug effects , Bone Marrow/metabolism , Caffeine/administration & dosage , Chlorpromazine/administration & dosage , DNA Damage , Drug Synergism , Humans , Male , Melanoma/metabolism , Melanoma/pathology , Mice , Mice, Nude , Semustine/administration & dosage , Tissue Distribution
2.
Cancer Chemother Pharmacol ; 18(3): 198-202, 1986.
Article in English | MEDLINE | ID: mdl-3026674

ABSTRACT

Following the clinical observation of enhanced antineoplastic action of etoposide in the presence of cyclosporin A (CyA), we investigated this drug interaction in several in vitro and in vivo tumor systems. Macromolecular DNA damage induced by etoposide at drug levels comparable to plasma AUC values achieved in patients was increased not only in leukemic peripheral blood cells from patients but also in mononuclear peripheral blood cells from a healthy donor. Intracellular retention of radioactivity from 3H-etoposide was increased by a factor of 1.5 at the most in the presence of CyA. The cytotoxicity of etoposide and adriamycin to L 1210 leukemic cells was clearly enhanced, whereas CyA had no effect on the action of cisplatin or ionizing irradiation. At CyA blood levels not exceeding 1.44 microgram/ml, increased tumor inhibition of etoposide was observed in a human embryonal cancer xenograft, but there was also higher lethality in normal mice. We conclude from our own data and from other recent findings that with respect to chemosensitization the effects of CyA resemble those of calcium channel blockers or anticalmodulin agents. In contrast to calcium channel blockers, however, adequate plasma levels of CyA can well be achieved in patients.


Subject(s)
Cyclosporins/pharmacology , Etoposide/pharmacology , Animals , Cells, Cultured , Cisplatin/pharmacology , Cyclosporins/administration & dosage , Cyclosporins/metabolism , Doxorubicin/administration & dosage , Doxorubicin/pharmacology , Drug Interactions , Etoposide/administration & dosage , Etoposide/metabolism , Humans , Lethal Dose 50 , Leukemia L1210/drug therapy , Leukemia, Myeloid, Acute/drug therapy , Lymphoma, Non-Hodgkin/drug therapy , Male , Mice , Neoplasm Transplantation , Neoplasms, Germ Cell and Embryonal/drug therapy , Radiation, Ionizing
3.
Invest New Drugs ; 2(2): 161-8, 1984.
Article in English | MEDLINE | ID: mdl-6469510

ABSTRACT

Cyclophosphamide (CPA) is widely used against leukemic and lymphoproliferative diseases, but in vitro studies on response to this agent so far have been limited to instable derivatives with poor galenic properties. ASTA Z 7557 is a newly synthesized "activated cyclophosphamide" that circumvents the need for hepatic activation and has good stability. The critical cytotoxic lesions after exposure to bifunctional alkylating agents presumably are DNA interstrand crosslinks (ISC). We have, therefore, examined the formation and apparent removal of ISC after in vitro treatment with ASTA Z 7557 by use of the highly sensitive alkaline elution technique. Survival of murine L1210 cells was determined after 1 hour in vitro exposure with a D 37 value of 5.7 micrograms/ml (from the initial shoulder part of the survival curve) and a Do value of 1.5 micrograms/ml (from the exponential part of the curve). Previous labelling of L1210 cells by 125IUdR simplified the alkaline elution procedure but there was some cytotoxicity of the radiochemical itself with a reduction of cloning efficiency from 77% to 61%. The maximum of ISC was observed at 6 h after initiation of treatment with much of the damage apparently removed at 24 h. The simultaneous presence of DNA single strand breaks (SSB), however, confounds the analysis of DNA damage at 24 h and early cytolysis and unaided death of human lymphocytes often preclude the analysis of macromolecular damage at this time. Human peripheral blood cells isolated from patients with leukemic or lymphoproliferative diseases showed a remarkable heterogeneity with regard to the formation of ISC at 3 h.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Cross-Linking Reagents/pharmacology , Cyclophosphamide/analogs & derivatives , DNA Repair/drug effects , DNA, Neoplasm/metabolism , DNA, Single-Stranded/metabolism , Leukemia L1210/metabolism , Leukemia/metabolism , Animals , Cell Survival/drug effects , Cells, Cultured , Cyclophosphamide/pharmacology , Humans , Kinetics , Leukemia/drug therapy , Leukemia/pathology , Leukemia L1210/drug therapy , Leukemia L1210/pathology , Mice
4.
Cancer Chemother Pharmacol ; 11(3): 147-52, 1983.
Article in English | MEDLINE | ID: mdl-6227420

ABSTRACT

The development of nitrosoureas has switched from more lipophilic derivatives to congeners with higher water-solubility, since this property was presumably associated with a decrease in myelosuppression. We have compared the therapeutic efficacy of clinically well-known lipophilic nitrosoureas BCNU, CCNU, and MeCCNU with the recently introduced water-soluble nitrosoureas chlorozotocin (CZT) and hydroxyethyl-CNU (HeCNU), using a human melanoma xenograft system. There were considerable differences in tumor-inhibitory activity, with HeCNU ranking first and CZT last, and the rank order was similar for drug-induced lethality or bone marrow damage (in terms of reduced cellularity or macromolecular DNA damage). When the doses are expressed as percentages of the corresponding LD10/30 values, CZT ranks last and HeCNU low among conventional nitrosoureas. We conclude that water-solubility is not associated with reduced myelosuppression and that other guidelines will have to be adopted for rational development of nitrosoureas.


Subject(s)
Brain Neoplasms/drug therapy , Melanoma/drug therapy , Nitrosourea Compounds/therapeutic use , Animals , Bone Marrow/drug effects , Carmustine/therapeutic use , Dose-Response Relationship, Drug , Female , Humans , Lomustine/therapeutic use , Male , Mice , Mice, Nude , Neoplasm Transplantation , Semustine/therapeutic use , Streptozocin/analogs & derivatives , Streptozocin/therapeutic use , Transplantation Immunology/drug effects , Transplantation, Heterologous
SELECTION OF CITATIONS
SEARCH DETAIL